Business Context and Reporting Period
This Form 8-K is a current report filed by IRIDEX CORPORATION on October 2, 2017. The filing discloses the entry into a material definitive agreement regarding the hiring of a new executive officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
Material Changes
The primary material change reported is the appointment of George Marcellino, a current member of the Board of Directors, as Vice President, Clinical Affairs, effective October 2, 2017. Mr. Marcellino will continue to serve on the Board on an interim basis until a replacement is appointed.
Management Commentary and Compensation Details
The offer letter dated September 6, 2017, outlines the following compensation package for Mr. Marcellino:
- Annual Salary: $300,000.
- Performance Bonus: Up to $30,000 under the 2017 Management by Objectives Plan, contingent on specific individual objectives and company revenue, earnings, and operational targets.
- Stock Options: Option to purchase 30,000 shares of common stock. Vesting schedule: 25% on the one-year anniversary, with the remainder vesting in equal monthly installments over the subsequent three years.
- Restricted Stock Units (RSUs): Grant of 25,000 shares. Vesting schedule: 25% on the one-year anniversary, with the remainder vesting in equal monthly installments over the subsequent three years.
Investor Verification Checklist
- Verify the total equity dilution impact of the 30,000 stock options and 25,000 RSUs granted.
- Review the specific revenue and earnings targets required to trigger the $30,000 performance bonus.
- Confirm the timeline for appointing a replacement board member to fill Mr. Marcellino's interim vacancy.
- Examine the full text of the Offer Letter (Exhibit 10.1) for additional terms not summarized in the filing.